Special Issue

Gene Therapy for Neurological Disease

Message from the Guest Editors

Gene therapy is emerging as an exciting therapeutic strategy, not only for rare monogenic diseases, for which gene replacement is the main goal, but also for a wide range of neurodegenerative disorders with complex pathogenesis, for which gene delivery of novel therapeutic targets is a promising approach. Several drugs are now accessing the market and facilitating the development of new approaches and new routes of delivery to better target the central and peripheral nervous system. In this Special Issue, we want to review the current status of gene therapy for neurodegenerative disorders, present the last results in the field with all kind of approaches (including in vivo or ex vivo gene therapy), and also review emerging next-generation technologies.

Guest Editors

Dr. Caroline Sevin

Dr. Francoise Piguet

Dr. Kumaran Deiva

Deadline for manuscript submissions

closed (31 March 2024)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/139967

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

